Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the stock a "buy" rating in a report on Thursday, August 4th. Evercore ISI lifted their price objective on Alnylam Pharmaceuticals to $252.00 in a report on Tuesday. William Blair began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, June 7th. They set an "outperform" rating on the stock. SVB Leerink lifted their target price on Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the company a "market perform" rating in a research report on Wednesday, June 15th. Finally, HC Wainwright lifted their target price on Alnylam Pharmaceuticals from $400.00 to $430.00 in a research report on Monday, May 2nd. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $227.29.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $232.00 on Thursday. Alnylam Pharmaceuticals has a 12 month low of $117.58 and a 12 month high of $233.88. The stock has a fifty day moving average price of $151.41 and a 200-day moving average price of $149.86. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 3.85. The firm has a market cap of $27.85 billion, a PE ratio of -28.40 and a beta of 0.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Rating) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative net margin of 110.91% and a negative return on equity of 204.18%. The business had revenue of $224.80 million for the quarter, compared to analysts' expectations of $256.06 million. During the same quarter in the prior year, the company posted ($1.61) EPS. The business's revenue for the quarter was up 1.9% on a year-over-year basis. Equities research analysts predict that Alnylam Pharmaceuticals will post -8.14 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,841 shares of the company's stock in a transaction on Friday, August 5th. The stock was sold at an average price of $218.16, for a total value of $401,632.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 5,349 shares of company stock valued at $1,033,073 in the last ninety days. Company insiders own 1.40% of the company's stock.